Calcorp Ltd (CALC)
PSX 
Summary
CALC Chart
Airbus Clinches Contract to Supply 30 A320neo Aircraft to CALC
EADSY lands a firm order for 30 A320neo aircraft from CALC, reinforcing strong global demand for its fuel-efficient single-aisle aircraft.
CalciMedica Inc. (CALC) Moves to Buy: Rationale Behind the Upgrade
CalciMedica Inc. (CALC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does CalciMedica Inc. (CALC) Have the Potential to Rally 232.3% as Wall Street Analysts Expect?
The consensus price target hints at a 232.3% upside potential for CalciMedica Inc. (CALC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Calcorp Ltd (CALC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Calcorp Ltd ever had a stock split?
Calcorp Ltd Profile
| Biotechnology Industry | Healthcare Sector | A. Rachel Leheny CEO | PSX Exchange | US38942Q2021 ISIN |
| US Country | 14 Employees | - Last Dividend | 20 Mar 2023 Last Split | - IPO Date |
Overview
CalciMedica, Inc. is a clinical-stage biopharmaceutical company with a focus on developing therapeutic solutions for illnesses resulting from inflammatory and immunologic processes as well as direct cellular damage. Operating from its base in La Jolla, California, the company seeks to address significant unmet medical needs by targeting calcium release-activated (CRAC) channels, which play a crucial role in the function of immune and inflammatory responses. As a pioneer in the field, CalciMedica, Inc. is advancing a promising pipeline of CRAC channel inhibitors designed to offer novel treatments for acute and chronic conditions alike.
Products and Services
- Auxora
Auxora stands as the lead product candidate of CalciMedica, Inc., representing an intravenous formulation of a small molecule CRAC channel inhibitor. Auxora is currently under clinical development, being tested in phase 2 trials for several critical conditions. These include acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury. Moreover, Auxora is being evaluated for its efficacy in treating severe COVID-19 pneumonia, marking a significant stride towards addressing the ongoing pandemic-related challenges.
- CM6336
CM6336 represents an innovative approach to chronic inflammatory diseases, being an oral CRAC channel inhibitor under development by CalciMedica, Inc. This drug is tailored to modulate the inflammatory process from within, offering a novel solution for patients suffering from chronic conditions driven by inflammatory mechanisms. The development of CM6336 underscores CalciMedica's commitment to expanding its therapeutic offerings beyond acute care into managing long-term inflammatory diseases.
- Auxora for Acute Ulcerative Colitis and Allergic Asthma
In addition to its applications for pancreatitis, pancreatic toxicity, kidney injury, and COVID-19 pneumonia, Auxora is also being explored as a treatment option for acute ulcerative colitis and allergic asthma. This extension of Auxora’s application highlights the flexibility and potential of CalciMedica’s CRAC channel inhibition technology to provide relief in a variety of inflammatory and immunologic conditions, further establishing the company’s role in pioneering new paths for the treatment of complex diseases.
